TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02883062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Undergo lumpectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy
Description: Undergo mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Description: Undergo mastectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02778100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: Administered intranasally.
Study: NCT03113474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food palatability
Description: Food palatability is modulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food palatability
Description: Food palatability is modulated
Study: NCT02671448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home monitoring teleconsult visits
Description: A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes (PRO)
Description: Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Reported Outcomes instruments
Description: Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
Study: NCT00815282

Intervention type: OTHER
Group type: OTHER
Intervention: Human papilloma virus vaccine (cervarix)
Description: vaccination at 0, 1 and 6 months
Study: NCT00671931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dexmedetomidine, low propofol
Description: Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dexmedetomidine, low propofol
Description: Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidin
Description: Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
Study: NCT01249248

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes

Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
Study: NCT01975896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
Study: NCT02507648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 1 tablet contains 75 mg oseltamivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamiflu®
Description: 1 tablet contains 75 mg oseltamivir
Study: NCT05437081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latino Emerging Adults (LEA)
Description: The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
Study: NCT01169675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low dose
Description: patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high dose
Description: patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle
Study: NCT04150796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral Hernia Repair
Description: Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
Study: NCT01169675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high dose 6 day
Description: patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low dose 6 day
Description: patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
Study: NCT01082263

Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
Study: NCT03445546

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic test of platelet function
Description: Light transmittance aggregometry and VerifyNow

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic test of platelet function
Description: Light transmittance aggregometry and VerifyNow
Study: NCT01194999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling procedure
Description: The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
Study: NCT02001844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trial Foot Orthoses (FOs)
Description: Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo foot orthoses (FOs)
Description: The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial.
Study: NCT04927832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUDOSCAN and EMG (electromyogram)
Description: The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUDOSCAN and EMG (electromyogram)
Description: The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG
Study: NCT01169675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium dose 6 day
Description: patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium dose
Description: patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
Study: NCT00445679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Description: Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Description: Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Description: Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: 20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
Study: NCT04445480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Popliteal block
Description: Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
Study: NCT03375983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage infection of P.vivax
Description: The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
Study: NCT03815877

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nescafe Gold ® coffee
Description: Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nescafe Gold DECAF® coffee
Description: Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery.
Study: NCT00707681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS-20
Description: 4 ml/vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4ml/vial
Study: NCT02146196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 weeks robotic assisted training with the Lokomat®
Description: During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One week robotic assisted gait training with the Lokomat®
Description: During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
Study: NCT05736640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03762863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet application skill retention
Description: Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
Study: NCT03688178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Varlilumab is an agonist anti-CD27 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td
Description: A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
Study: NCT00679523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Solution, 7.5%
Description: Once daily application for 180 days
Study: NCT03931083

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for CIN2+/HSIL
Description: The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for CIN2+/HSIL
Description: The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for CIN2+/HSIL
Description: The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for CIN2+/HSIL
Description: The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
Study: NCT04381884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
Description: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
Study: NCT04223505

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ECG-gated cardiac CT (CCT)
Description: Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography (TEE)
Description: TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal Echocardiography (TEE)
Description: TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
Study: NCT03752593

Intervention type: OTHER
Intervention: ET Tube
Description: Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia

Intervention type: OTHER
Intervention: ET Tube
Description: Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
Study: NCT00185419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: 30 µg ethinylestradiol, 3mg drospirenone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: 30 µg ethinylestradiol, 150 µg desogestrel
Study: NCT02174939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: One tablet (100 mg) twice per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Placebo
Description: One tablet twice per day for 12 weeks
Study: NCT01820377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aboriginal Youth Mentorship Program
Description: High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
Study: NCT03688178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td
Description: A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unpulsed DCs
Description: Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.